세계 과민성 방광(OAB) 치료 시장 규모는 2024-2031년의 예측 기간 동안 4.10%의 연평균 복합 성장률(CAGR)로 성장하여 2023년 40억 1,000만 달러에서 2031년 55억 3,000만 달러에 달할 것으로 예상됩니다. 이 시장은 최근 몇 년동안 괄목할 만한 성장세를 보였으며, 앞으로도 강력한 성장세를 유지할 것으로 예상됩니다. 과민성 방광은 빈뇨, 절박뇨, 요실금, 소변 누출, 야간 최소 2회 이상 배뇨 요구 등 다양한 증상을 포함하는 증후군으로 분류됩니다. 과민성 방광은 골반 근육 약화, 외상이나 질병으로 인한 신경 손상, 요로감염(UTI), 비만, 폐경 후 호르몬 균형 장애, 약물, 카페인 및 알코올 섭취 등 다양한 요인이 관여합니다.
과민성 방광(OAB)에 대한 인식 증가와 혁신적인 제형 개발을 위한 R&D 투자 등의 요인이 세계 과민성 방광(OAB) 치료제 시장을 견인할 것으로 예상됩니다. 또한 과민성 방광(OAB) 치료제 및 치료제에 대한 높은 수요에 따른 경쟁의 급증과 의약품 제조에 주력하는 주요 기업의 존재는 수요를 촉진하는 중요한 요인으로 작용하고 있습니다. 인구의 과민성 방광과 요실금에 대한 인식이 높아지면서 시장 성장에 더욱 박차를 가하고 있습니다. 또한, OAB를 겨냥한 새로운 제제 및 치료법 개발에 대한 투자가 증가하고 있는 것도 예측 기간 동안 시장 성장에 기여할 것으로 보입니다. 또한, 업계 참여자들은 경쟁이 치열한 시장에서 입지를 유지하기 위해 제휴 및 신제품 출시와 같은 다양한 전략을 채택하고 있습니다.
또한, 과민성 방광(OAB) 치료제를 제조하는 주요 기업들은 경쟁력을 유지하기 위해 제휴, 인수, 제품 출시, 승인 등 적극적인 사업 전략을 채택하고 있습니다. 또한, 특히 영국과 일본과 같은 국가에서 진화하는 규제 환경은 과민성 방광(OAB) 치료의 발전을 촉진하고 있습니다.
이 보고서는 세계의 과민성 방광(OAB) 치료제 시장을 조사했으며, 시장 개요와 함께 약물요법별/질환 유형별/유통 채널별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
Global overactive bladder treatment market is projected to witness a CAGR of 4.10% during the forecast period 2024-2031F, growing from USD 4.01 billion in 2023 to USD 5.53 billion in 2031F. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. Overactive bladder is categorized as a syndrome encompassing a range of symptoms, including frequent urination, an urgent need to urinate, urine leakage, and the requirement to urinate at least twice during the night. Various factors contribute to overactive bladder, such as weakened pelvic muscles, nerve damage resulting from trauma or diseases, urinary tract infection (UTI), obesity, hormonal imbalance post-menopause, medications, and the consumption of caffeine and alcohol.
Factors such as increased awareness of overactive bladder (OAB) and research and development investments for innovative formulations are expected to propel the global overactive bladder treatment market. Moreover, the surge in competition due to the high demand for OAB medications and treatments, coupled with major players focusing on drug manufacturing, is a crucial factor driving demand. The increasing awareness of OAB and urinary incontinence among the population further supports the market's growth. Additionally, the ongoing investments in developing novel formulations and treatments targeting OAB are poised to contribute to growth in the forecast period. Furthermore, industry participants are adopting various strategies, including collaborations and new product launches, to sustain their positions in this competitive market.
Furthermore, key players in the production of overactive bladder treatments are employing aggressive business strategies such as collaboration, acquisitions, product launches, and approvals to maintain competitiveness. Additionally, evolving regulatory landscapes, particularly in countries like the United Kingdom and Japan, expedite advancements in overactive bladder treatments. For instance, in March 2023, KYORIN Pharmaceutical Co., Ltd. entered into a collaboration with Sumitomo Pharma Co., Ltd. to jointly develop, manufacture, and market Vibegron for overactive bladder in Taiwan and various other Asian countries, including Singapore, Hong Kong, Indonesia, and Vietnam. Collaborations among key industry players are anticipated to enhance the availability of drugs and treatments across these countries, potentially fostering growth in the years ahead.
Rising Incidences of Overactive Bladder Drive the Market
One of the key drivers of overactive bladder treatment is the increasing prevalence of several diseases, such as diabetes, bladder cancer, Parkinson's, and stroke, as well as urinary tract infections (UTIs) and other neurological disorders that cause overactive bladder. UTIs are caused by bacteria that enter the urinary tract. Urinating too often and with urgency are symptoms of an overactive bladder caused by UTIs, in addition to pain and burning sensation during urination. As per an article published in November 2022 by StatPearls Journal, estimates are that 40% of American women would experience a urinary tract infection at least once. Consequently, the increasing frequency of UTIs will fuel the demand for OAB treatment medications. Furthermore, diabetes - especially uncontrolled diabetes - can impact the nerves that regulate the bladder, resulting in symptoms that are too active. Over time, nerve damage from high blood sugar can lead to problems with bladder control. Therefore, the rising incidence of diabetes could potentially increase the burden of overactive bladder in people. Approximately 422 million individuals globally suffer from diabetes, with the majority residing in low- and middle-income nations. The disease is directly responsible for 1.5 million fatalities annually. Over the past few decades, there has been a steady rise in both the number of cases and the incidence of diabetes.
Increasing Investments in R&D - A Primary Growth Catalyst
The increasing geriatric population, coupled with growing awareness about available treatments for overactive bladder syndrome, serves as the primary catalyst for the growth of the overactive bladder therapeutics market. Anticipated market expansion is driven by growth in demand for innovative medications, enhanced healthcare infrastructure, the influx of new pharmaceutical companies, a robust product pipeline, and the proliferation of generic medicine approvals resulting in reduced costs. Additionally, it is estimated that the growing number of clinical trials and the approval of novel drugs will support market expansion. Data from the third phase of EMPOWUR Extension Study of GEMTESA (Vibegron), 75 mg overactive bladder treatment medication therapy, was presented in May 2022 by Urovant Sciences. It confirmed the drug's long-term effects and provided confirmation on the medication's potential usefulness and durability in this patient population. Urge urine incontinence (UUI) events, urgency episodes, and average daily micturition all showed consistent decreases with the medication.
Neurostimulation to Dominate the Overactive Bladder Treatment Market
One minimally invasive method for treating OAB is neurostimulation, which involves electrical impulses being delivered to the bladder to control neurons. Through percutaneous or surgical means, the implantable device is positioned in close proximity to the sacral nerves. When a patient is not responding to previous therapy, controlled electrical stimulation can assist regulate bladder activity, reducing urgency, frequency and improving control.
The increased frequency of OAB and the widespread acceptance of neurostimulation therapy among patients who are not responding to medications like anticholinergics and mirabegron are the main drivers propelling the growth of this market. Sacral neuromodulation (SNM) is a highly adopted approach for OAB treatment in the United States for patients recalcitrant to pharmaceutical therapy because of its high efficacy, safety, and minimally invasive nature, according to an article published by the National Center for Biotechnology Information (NCBI)in May 2023. According to the same source, the procedure is popular in Europe and Canada for treating fecal incontinence, urgency, frequency, and urine incontinence. As a result, neurostimulation is seen as safer and more desirable than complicated procedures like surgery.
North America Dominates the Overactive Bladder Treatment Market
North America is anticipated to dominate the overactive bladder treatment market in the foreseeable future due to the increasing incidence of OAB and a surge in product launches in the region. As per a report in the Canadian Urological Association Journal from March 2023, approximately 18% of Canadians are presently dealing with OAB, and about 24% face challenges in adhering to pharmacotherapy. Consequently, the substantial OAB prevalence in Canada is expected to fuel the demand for diverse treatment modalities like neurostimulation and intravesical instillation throughout the forecast period. Moreover, the region's market growth is poised to accelerate in the forecast period, fuelled by an increasing number of collaborations and innovative drug launches led by prominent local players. Urovant Sciences joined forces with Thinx Inc. in November 2022 to unveil "Time to Go," a comprehensive educational campaign shedding light on the impact of OAB and presenting management options for symptoms among Americans. Additionally, in July 2022, Dr. Reddy's Laboratories Ltd. introduced Fesoterodine Fumarate Extended-Release Tablets, a generic therapeutic equivalent to Toviaz, in the United States. As the prevalence of OAB rises and awareness initiatives through partnerships gain momentum, coupled with the introduction of novel therapies, the regional market is anticipated to provide lucrative growth prospects in the forecast period.
Future Market Scenario (2024-2031F)
Increasing prevalence of overactive bladder is creating a demand for treatment options. People have become more aware of the disease, its further consequences, and its causes, which is causing them to adopt a healthier lifestyle. R&D and heavy investments made by government and healthcare giants are promoting developments in the overactive bladder market, and this is acting as a main driver for the market to flourish during the forecast period. In April 2022, Axonics, Inc., a global medical technology company specializing in innovative products for bladder and bowel dysfunction treatment, unveiled the widespread availability of the Axonics F15 throughout the United States. This recently developed sacral neuromodulation (SNM) system, distinguished by its extended lifespan and fully recharge-free design, received FDA approval in March 2022. The introduction of Axonics' recharge-free system marks significant progress for individuals dealing with bladder and bowel dysfunction.
Key Players Landscape and Outlook
There are a number of significant competitors the overactive bladder treatment industry. Presently, a number of the main competitors control the majority of the market share. Among the businesses that are currently governing the market shares are Astellas Pharma Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AbbVie Inc., Viatris Inc., Medtronic Plc, Endo International Plc., Lupin, Sun Pharmaceutical Industries Ltd., Glenmark, Amneal Pharmaceuticals LLC, Ajanta Pharma Ltd., Johnson & Johnson. The primary focus of these leading players is directed towards the rapidly expanding market segment, aiming to thrive and excel in an intensely competitive market environment. Additionally, these market players emphasize collaboration and license agreements as strategic initiatives anticipated to propel market growth.
In March 2023, MSN Laboratories introduced Fesobig, a generic version of Fesoterodine Fumarate, as an initial pharmacotherapy choice for managing overactive bladder (OAB).
In January 2023, Alembic Pharmaceuticals Limited obtained approval from the United States FDA for its Abbreviated New Drug Application (ANDA) related to Fesoterodine Fumarate tablets, designed for the treatment of OAB in adults.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.